Reinsurance, Stop-Loss Programs in Managing High-Cost Meds, Per Rick Lassow of Summit Re | AMCP 2023
At the annual AMCP meeting, Summit Re's Vice President of Actuarial & Underwriting, Rick Lassow, FSA, MAAA, led a discussion on managing high-cost medications through reinsurance and stop-loss programs. In this interview with Managed Healthcare Executive Lassow addresses high-cost cell and gene therapies ran through reinsurance and how Medicaid can benefit the most from reinsurance programs.
In this interview with Managed Healthcare Executive, Lassow addressed the situations of high-cost cell and gene therapies ran through reinsurance and how Medicaid can benefit the most from reinsurance programs.
As for gene and cell therapies, they're not much different from other high-investment drugs. He added these types of therapies could be more predictable when it comes to the patient condition because a gene therapy has a defined price take $2.5 to $3 million. Recovery time can be different, too. A burn victim, for example, can be treated differently or have different outcomes because these patients can be in the hospital for a week or more depending on the severity.
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Read More
Potential Generics Could Lower Prices for Oncology, Cardiovascular Drugs | AMCP 2024
April 18th 2024Up to 50 generics could be approved this year, including Victoza to treat patients with diabetes. If generics of Victoza become available, this would the first GLP-1 to face generic competition.
Read More
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
April 17th 2024Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.
Read More
